GlassScriptPhysician profile
Jill M Miscovich
NPI 1114433729
$9,795.69
in general payments reported to CMS, 2019-2025
43 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,414 · 2022: $2,282 · 2023: $2,360 · 2024: $2,263 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,099.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,549.26 | 2021-2025 | |
| Novo Nordisk INC | $1,855.89 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $662.00 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $602.15 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $506.34 | 2021-2024 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $482.18 | 2021-2025 | |
| Glaxosmithkline, LLC. | $330.21 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.31 | 2021-2025 | Jardiance |
| Shield Therapeutics INC | $214.08 | 2023-2024 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.26 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $189.42 | 2021-2022 | |
| Exact Sciences Corporation | $170.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $156.36 | 2022-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $128.17 | 2022-2024 | |
| Dexcom, INC. | $106.31 | 2021-2025 | Dexcom G6 Transmitter |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $101.09 | 2025 | Smartvest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.33 | 2021-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $76.41 | 2022 | |
| Idorsia Pharmaceuticals US INC | $74.97 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $71.94 | 2021-2023 | Eliquis |
| Neurocrine Biosciences, INC. | $71.32 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $71.25 | 2022-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $69.75 | 2021-2024 | Trintellix |
| Lundbeck LLC | $68.35 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $65.38 | 2022-2025 | Fanapt |
| Amgen INC. | $61.73 | 2022 | |
| Xeris Pharmaceuticals, INC. | $57.36 | 2021-2023 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $47.78 | 2022-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Insulet Corporation | $46.17 | 2024 | Omnipod |
| Almatica Pharma LLC | $43.65 | 2023 | Loreev Xr |
| Verona Pharma, INC. | $39.15 | 2025 | Ohtuvayre |
| Phadia US INC. | $38.37 | 2024 | Immunocap |
| Abiomed | $38.31 | 2024 | Impella |
| Medtronic, INC. | $37.94 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $36.50 | 2022 | |
| Ucb, INC. | $28.51 | 2024 | Briviact |
| Cequr Corporation | $19.24 | 2024 | Cequr Simplicity |
| Alkermes, INC. | $18.27 | 2023 | Aristada, Lybalvi |
| Sanofi-Aventis U.S. LLC | $14.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.37 | 2021 | |
| Tandem Diabetes Care, INC. | $14.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Axsome Therapeutics, INC. | $13.69 | 2023 | Auvelity |
| Currax Pharmaceuticals LLC | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Miscovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.